VanEck JP Morgan EM Local Currency Bond ETF vs McKesson Corporation — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $25.47, while McKesson Corporation trades at $840.54 (market cap $93.23B). The key difference: McKesson Corporation pays a 0.41% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none, and McKesson Corporation is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMLC | MCK | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $26.59 | $995.69 |
52-Week Low | $24.83 | $659.01 |
Market Cap | — | $93.23B |
Enterprise Value | — | $97.87B |
Dividend Yield | — | 0.41% |
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $25.47 with minimal daily movement (-0.06%). Technical indicators show a bullish trend with moving averages supporting upward momentum, though oscillators remain neutral. The ETF maintains consistent dividend payments of $0.14 per share quarterly, providing income stability. Recent news highlights growing institutional interest in emerging market debt as investors seek yield above Treasury bonds.
The outlook remains positive given the 6.1% yield advantage over Treasuries, though currency risk and capital erosion concerns persist. Short interest has surged 73% recently, indicating some skepticism about sustainability. Federal Reserve policy decisions will be crucial for EM debt performance through 2026.
MCK trades at $836.49, up 4.12% in the last session, with a neutral technical signal and strong analyst consensus. Recent earnings consistently beat expectations, with Q1 2026 EPS of $11.69 surpassing the $11.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins remain thin at 1.18%. The stock is supported by positive cash flow trends and a dividend payout scheduled for July 2026.
The outlook is positive, driven by earnings momentum and a $932.83 consensus price target implying 11.5% upside. Risks include low profitability margins and high liabilities, but institutional sentiment is bullish with 80% buy ratings. Investors should weigh growth in specialty pharma against execution and regulatory pressures in the healthcare sector.
Trailing returns across standard periods
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →